Advanced search
1 file | 559.73 KB Add to list

A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?

(2011) EUROPEAN RESPIRATORY JOURNAL. 38(5). p.1200-1214
Author
Organization
Abstract
In chronic obstructive pulmonary disease (COPD) patients, pulmonary rehabilitation is a nonpharmacological intervention aimed at improving physical exercise tolerance, dyspnoea and perceived quality of life. However, identifying predictors of clinical response and which patients achieve benefit remains a difficult question to answer with no conclusive data available. Baseline characteristics of COPD patients, such as degree of breathlessness, body weight and arterial partial pressure of oxygen, generally appear to be too direct to have a correlation with improvement of post-rehabilitation outcomes. Furthermore, some additional benefits of patients treated with rehabilitation are simply not detected by usual measures (social interaction, sleep quality and confidence). Although there are some data suggesting that some medical conditions frequently associated with COPD (osteoporosis, metabolic syndrome and heart diseases) may negatively influence rehabilitation outcomes, at present the evidence is contradictory.
Keywords
chronic obstructive pulmonary disease, comorbidities, Attendance, effectiveness, minimum clinically important difference, predictors, pulmonary rehabilitation, INDUCED AIRWAY INFLAMMATION, IDIOPATHIC PULMONARY-FIBROSIS, ACUTE RESPIRATORY-DISTRESS, SMOKE-INDUCED EMPHYSEMA, ISCHEMIA-REPERFUSION INJURY, BRONCHIOLITIS OBLITERANS SYNDROME, DIISOCYANATE-INDUCED ASTHMA, TUMOR-NECROSIS-FACTOR, BREAST-CANCER MODEL, TISSUE INHIBITOR

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 559.73 KB

Citation

Please use this url to cite or link to this publication:

MLA
Vandenbroucke, Roosmarijn, Eline Dejonckheere, and Claude Libert. “A Therapeutic Role for Matrix Metalloproteinase Inhibitors in Lung Diseases?” EUROPEAN RESPIRATORY JOURNAL 38.5 (2011): 1200–1214. Print.
APA
Vandenbroucke, Roosmarijn, Dejonckheere, E., & Libert, C. (2011). A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? EUROPEAN RESPIRATORY JOURNAL, 38(5), 1200–1214.
Chicago author-date
Vandenbroucke, Roosmarijn, Eline Dejonckheere, and Claude Libert. 2011. “A Therapeutic Role for Matrix Metalloproteinase Inhibitors in Lung Diseases?” European Respiratory Journal 38 (5): 1200–1214.
Chicago author-date (all authors)
Vandenbroucke, Roosmarijn, Eline Dejonckheere, and Claude Libert. 2011. “A Therapeutic Role for Matrix Metalloproteinase Inhibitors in Lung Diseases?” European Respiratory Journal 38 (5): 1200–1214.
Vancouver
1.
Vandenbroucke R, Dejonckheere E, Libert C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? EUROPEAN RESPIRATORY JOURNAL. 2011;38(5):1200–14.
IEEE
[1]
R. Vandenbroucke, E. Dejonckheere, and C. Libert, “A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?,” EUROPEAN RESPIRATORY JOURNAL, vol. 38, no. 5, pp. 1200–1214, 2011.
@article{1963696,
  abstract     = {In chronic obstructive pulmonary disease (COPD) patients, pulmonary rehabilitation is a nonpharmacological intervention aimed at improving physical exercise tolerance, dyspnoea and perceived quality of life. However, identifying predictors of clinical response and which patients achieve benefit remains a difficult question to answer with no conclusive data available. 
Baseline characteristics of COPD patients, such as degree of breathlessness, body weight and arterial partial pressure of oxygen, generally appear to be too direct to have a correlation with improvement of post-rehabilitation outcomes. Furthermore, some additional benefits of patients treated with rehabilitation are simply not detected by usual measures (social interaction, sleep quality and confidence). 
Although there are some data suggesting that some medical conditions frequently associated with COPD (osteoporosis, metabolic syndrome and heart diseases) may negatively influence rehabilitation outcomes, at present the evidence is contradictory.},
  author       = {Vandenbroucke, Roosmarijn and Dejonckheere, Eline and Libert, Claude},
  issn         = {0903-1936},
  journal      = {EUROPEAN RESPIRATORY JOURNAL},
  keywords     = {chronic obstructive pulmonary disease,comorbidities,Attendance,effectiveness,minimum clinically important difference,predictors,pulmonary rehabilitation,INDUCED AIRWAY INFLAMMATION,IDIOPATHIC PULMONARY-FIBROSIS,ACUTE RESPIRATORY-DISTRESS,SMOKE-INDUCED EMPHYSEMA,ISCHEMIA-REPERFUSION INJURY,BRONCHIOLITIS OBLITERANS SYNDROME,DIISOCYANATE-INDUCED ASTHMA,TUMOR-NECROSIS-FACTOR,BREAST-CANCER MODEL,TISSUE INHIBITOR},
  language     = {eng},
  number       = {5},
  pages        = {1200--1214},
  title        = {A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?},
  url          = {http://dx.doi.org/10.1183/09031936.00027411},
  volume       = {38},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: